nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—Formoterol—chronic obstructive pulmonary disease	0.202	1	CrCtD
Arformoterol—asthma—chronic obstructive pulmonary disease	0.165	1	CtDrD
Arformoterol—Adrenergic beta2-Agonists—Formoterol—chronic obstructive pulmonary disease	0.145	0.5	CiPCiCtD
Arformoterol—Adrenergic beta2-Agonists—Salbutamol—chronic obstructive pulmonary disease	0.145	0.5	CiPCiCtD
Arformoterol—ADRB2—chronic obstructive pulmonary disease	0.0707	1	CbGaD
Arformoterol—Dobutamine—Formoterol—chronic obstructive pulmonary disease	0.028	0.225	CrCrCtD
Arformoterol—Fenoterol—Formoterol—chronic obstructive pulmonary disease	0.0217	0.175	CrCrCtD
Arformoterol—Ritodrine—Formoterol—chronic obstructive pulmonary disease	0.0217	0.175	CrCrCtD
Arformoterol—Arbutamine—Formoterol—chronic obstructive pulmonary disease	0.019	0.153	CrCrCtD
Arformoterol—ADRB2—Salbutamol—chronic obstructive pulmonary disease	0.018	0.169	CbGbCtD
Arformoterol—ADRB1—Salbutamol—chronic obstructive pulmonary disease	0.0177	0.167	CbGbCtD
Arformoterol—ADRB2—Formoterol—chronic obstructive pulmonary disease	0.0136	0.128	CbGbCtD
Arformoterol—ADRB1—Formoterol—chronic obstructive pulmonary disease	0.0134	0.126	CbGbCtD
Arformoterol—Isoprenaline—Formoterol—chronic obstructive pulmonary disease	0.0124	0.1	CrCrCtD
Arformoterol—Labetalol—Formoterol—chronic obstructive pulmonary disease	0.012	0.0967	CrCrCtD
Arformoterol—CYP2A6—Formoterol—chronic obstructive pulmonary disease	0.0109	0.102	CbGbCtD
Arformoterol—Isoprenaline—Salbutamol—chronic obstructive pulmonary disease	0.00943	0.076	CrCrCtD
Arformoterol—CYP2A6—Montelukast—chronic obstructive pulmonary disease	0.00823	0.0776	CbGbCtD
Arformoterol—CYP2A6—Prednisolone—chronic obstructive pulmonary disease	0.00483	0.0455	CbGbCtD
Arformoterol—CYP2C19—Formoterol—chronic obstructive pulmonary disease	0.00449	0.0424	CbGbCtD
Arformoterol—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.00373	0.0352	CbGbCtD
Arformoterol—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.00341	0.0322	CbGbCtD
Arformoterol—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.00304	0.0287	CbGbCtD
Arformoterol—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.00283	0.0267	CbGbCtD
Arformoterol—CYP2C19—Prednisone—chronic obstructive pulmonary disease	0.00189	0.0178	CbGbCtD
Arformoterol—Fenoterol—ADRB2—chronic obstructive pulmonary disease	0.00012	0.159	CrCbGaD
Arformoterol—Ritodrine—ADRB2—chronic obstructive pulmonary disease	0.00012	0.159	CrCbGaD
Arformoterol—Arbutamine—ADRB2—chronic obstructive pulmonary disease	0.000112	0.149	CrCbGaD
Arformoterol—Formoterol—ADRB2—chronic obstructive pulmonary disease	0.000109	0.145	CrCbGaD
Arformoterol—Dobutamine—ADRB2—chronic obstructive pulmonary disease	0.000103	0.137	CrCbGaD
Arformoterol—Labetalol—ADRB2—chronic obstructive pulmonary disease	7.96e-05	0.106	CrCbGaD
Arformoterol—Isoprenaline—ADRB2—chronic obstructive pulmonary disease	5.86e-05	0.0778	CrCbGaD
Arformoterol—Isoprenaline—CYP1A1—chronic obstructive pulmonary disease	5.03e-05	0.0667	CrCbGaD
Arformoterol—ADRB1—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	3.82e-05	0.00793	CbGpPWpGaD
Arformoterol—ADRB2—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	3.74e-05	0.00776	CbGpPWpGaD
Arformoterol—CYP2C19—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	3.72e-05	0.00773	CbGpPWpGaD
Arformoterol—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	3.64e-05	0.00755	CbGpPWpGaD
Arformoterol—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	3.63e-05	0.00753	CbGpPWpGaD
Arformoterol—CYP2A6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	3.58e-05	0.00743	CbGpPWpGaD
Arformoterol—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	3.56e-05	0.00739	CbGpPWpGaD
Arformoterol—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—chronic obstructive pulmonary disease	3.55e-05	0.00738	CbGpPWpGaD
Arformoterol—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	3.53e-05	0.00732	CbGpPWpGaD
Arformoterol—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	3.42e-05	0.00711	CbGpPWpGaD
Arformoterol—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	3.39e-05	0.00704	CbGpPWpGaD
Arformoterol—CYP2A6—NRF2 pathway—SOD3—chronic obstructive pulmonary disease	3.25e-05	0.00675	CbGpPWpGaD
Arformoterol—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	3.18e-05	0.00659	CbGpPWpGaD
Arformoterol—ADRB1—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	3.17e-05	0.00657	CbGpPWpGaD
Arformoterol—CYP2C19—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	3.07e-05	0.00637	CbGpPWpGaD
Arformoterol—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	2.94e-05	0.0061	CbGpPWpGaD
Arformoterol—CYP2C19—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	2.88e-05	0.00597	CbGpPWpGaD
Arformoterol—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	2.82e-05	0.00586	CbGpPWpGaD
Arformoterol—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	2.64e-05	0.00549	CbGpPWpGaD
Arformoterol—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	2.64e-05	0.00547	CbGpPWpGaD
Arformoterol—CYP2A6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	2.6e-05	0.0054	CbGpPWpGaD
Arformoterol—Mental disorder—Montelukast—chronic obstructive pulmonary disease	2.56e-05	0.00068	CcSEcCtD
Arformoterol—CYP2C19—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	2.56e-05	0.00531	CbGpPWpGaD
Arformoterol—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	2.55e-05	0.000678	CcSEcCtD
Arformoterol—Tension—Formoterol—chronic obstructive pulmonary disease	2.55e-05	0.000677	CcSEcCtD
Arformoterol—Immune system disorder—Salbutamol—chronic obstructive pulmonary disease	2.54e-05	0.000676	CcSEcCtD
Arformoterol—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	2.54e-05	0.000676	CcSEcCtD
Arformoterol—Injury—Prednisolone—chronic obstructive pulmonary disease	2.54e-05	0.000675	CcSEcCtD
Arformoterol—Mediastinal disorder—Salbutamol—chronic obstructive pulmonary disease	2.54e-05	0.000674	CcSEcCtD
Arformoterol—Nervousness—Formoterol—chronic obstructive pulmonary disease	2.52e-05	0.00067	CcSEcCtD
Arformoterol—Insomnia—Aminophylline—chronic obstructive pulmonary disease	2.52e-05	0.000669	CcSEcCtD
Arformoterol—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	2.52e-05	0.000669	CcSEcCtD
Arformoterol—Back pain—Formoterol—chronic obstructive pulmonary disease	2.51e-05	0.000667	CcSEcCtD
Arformoterol—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	2.5e-05	0.000663	CcSEcCtD
Arformoterol—Leukocytosis—Prednisone—chronic obstructive pulmonary disease	2.49e-05	0.000661	CcSEcCtD
Arformoterol—Nausea—Roflumilast—chronic obstructive pulmonary disease	2.48e-05	0.000659	CcSEcCtD
Arformoterol—Mental disorder—Salbutamol—chronic obstructive pulmonary disease	2.47e-05	0.000656	CcSEcCtD
Arformoterol—Malnutrition—Salbutamol—chronic obstructive pulmonary disease	2.45e-05	0.000651	CcSEcCtD
Arformoterol—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	2.45e-05	0.000651	CcSEcCtD
Arformoterol—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	2.44e-05	0.00065	CcSEcCtD
Arformoterol—Tremor—Formoterol—chronic obstructive pulmonary disease	2.43e-05	0.000646	CcSEcCtD
Arformoterol—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	2.41e-05	0.00064	CcSEcCtD
Arformoterol—Tension—Salbutamol—chronic obstructive pulmonary disease	2.41e-05	0.000639	CcSEcCtD
Arformoterol—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	2.4e-05	0.000638	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	2.39e-05	0.000636	CcSEcCtD
Arformoterol—Agitation—Formoterol—chronic obstructive pulmonary disease	2.39e-05	0.000634	CcSEcCtD
Arformoterol—Tremor—Montelukast—chronic obstructive pulmonary disease	2.38e-05	0.000633	CcSEcCtD
Arformoterol—Nervousness—Salbutamol—chronic obstructive pulmonary disease	2.38e-05	0.000633	CcSEcCtD
Arformoterol—Insomnia—Tiotropium—chronic obstructive pulmonary disease	2.37e-05	0.000631	CcSEcCtD
Arformoterol—Angioedema—Formoterol—chronic obstructive pulmonary disease	2.37e-05	0.00063	CcSEcCtD
Arformoterol—Back pain—Salbutamol—chronic obstructive pulmonary disease	2.37e-05	0.00063	CcSEcCtD
Arformoterol—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	2.36e-05	0.000626	CcSEcCtD
Arformoterol—Malaise—Formoterol—chronic obstructive pulmonary disease	2.34e-05	0.000622	CcSEcCtD
Arformoterol—Agitation—Montelukast—chronic obstructive pulmonary disease	2.34e-05	0.000621	CcSEcCtD
Arformoterol—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	2.33e-05	0.00484	CbGpPWpGaD
Arformoterol—Angioedema—Montelukast—chronic obstructive pulmonary disease	2.32e-05	0.000618	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—SERPINA1—chronic obstructive pulmonary disease	2.32e-05	0.00481	CbGpPWpGaD
Arformoterol—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	2.31e-05	0.000614	CcSEcCtD
Arformoterol—Tremor—Salbutamol—chronic obstructive pulmonary disease	2.3e-05	0.00061	CcSEcCtD
Arformoterol—Palpitations—Formoterol—chronic obstructive pulmonary disease	2.29e-05	0.00061	CcSEcCtD
Arformoterol—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	2.28e-05	0.000605	CcSEcCtD
Arformoterol—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	2.27e-05	0.000604	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Tiotropium—chronic obstructive pulmonary disease	2.27e-05	0.000602	CcSEcCtD
Arformoterol—Cough—Formoterol—chronic obstructive pulmonary disease	2.27e-05	0.000602	CcSEcCtD
Arformoterol—CYP2C19—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	2.26e-05	0.0047	CbGpPWpGaD
Arformoterol—Agitation—Salbutamol—chronic obstructive pulmonary disease	2.25e-05	0.000599	CcSEcCtD
Arformoterol—Palpitations—Montelukast—chronic obstructive pulmonary disease	2.25e-05	0.000597	CcSEcCtD
Arformoterol—Constipation—Tiotropium—chronic obstructive pulmonary disease	2.25e-05	0.000597	CcSEcCtD
Arformoterol—Hypertension—Formoterol—chronic obstructive pulmonary disease	2.24e-05	0.000596	CcSEcCtD
Arformoterol—Angioedema—Salbutamol—chronic obstructive pulmonary disease	2.24e-05	0.000595	CcSEcCtD
Arformoterol—Cough—Montelukast—chronic obstructive pulmonary disease	2.22e-05	0.00059	CcSEcCtD
Arformoterol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	2.21e-05	0.00459	CbGpPWpGaD
Arformoterol—Urticaria—Aminophylline—chronic obstructive pulmonary disease	2.21e-05	0.000588	CcSEcCtD
Arformoterol—Malaise—Salbutamol—chronic obstructive pulmonary disease	2.21e-05	0.000588	CcSEcCtD
Arformoterol—Myalgia—Formoterol—chronic obstructive pulmonary disease	2.21e-05	0.000587	CcSEcCtD
Arformoterol—Chest pain—Formoterol—chronic obstructive pulmonary disease	2.21e-05	0.000587	CcSEcCtD
Arformoterol—Arthralgia—Formoterol—chronic obstructive pulmonary disease	2.21e-05	0.000587	CcSEcCtD
Arformoterol—Anxiety—Formoterol—chronic obstructive pulmonary disease	2.2e-05	0.000585	CcSEcCtD
Arformoterol—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	2.2e-05	0.000585	CcSEcCtD
Arformoterol—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	2.2e-05	0.000585	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Formoterol—chronic obstructive pulmonary disease	2.2e-05	0.000583	CcSEcCtD
Arformoterol—Discomfort—Formoterol—chronic obstructive pulmonary disease	2.18e-05	0.00058	CcSEcCtD
Arformoterol—CYP2C19—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	2.18e-05	0.00453	CbGpPWpGaD
Arformoterol—Palpitations—Salbutamol—chronic obstructive pulmonary disease	2.17e-05	0.000576	CcSEcCtD
Arformoterol—Myalgia—Montelukast—chronic obstructive pulmonary disease	2.16e-05	0.000575	CcSEcCtD
Arformoterol—Arthralgia—Montelukast—chronic obstructive pulmonary disease	2.16e-05	0.000575	CcSEcCtD
Arformoterol—Dry mouth—Formoterol—chronic obstructive pulmonary disease	2.16e-05	0.000574	CcSEcCtD
Arformoterol—Anxiety—Montelukast—chronic obstructive pulmonary disease	2.16e-05	0.000573	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	2.15e-05	0.000571	CcSEcCtD
Arformoterol—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	2.15e-05	0.000571	CcSEcCtD
Arformoterol—Dry skin—Prednisolone—chronic obstructive pulmonary disease	2.14e-05	0.000569	CcSEcCtD
Arformoterol—Cough—Salbutamol—chronic obstructive pulmonary disease	2.14e-05	0.000569	CcSEcCtD
Arformoterol—CYP2A6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	2.14e-05	0.00444	CbGpPWpGaD
Arformoterol—Oedema—Formoterol—chronic obstructive pulmonary disease	2.12e-05	0.000563	CcSEcCtD
Arformoterol—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	2.12e-05	0.000563	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—GCLC—chronic obstructive pulmonary disease	2.12e-05	0.0044	CbGpPWpGaD
Arformoterol—Hypertension—Salbutamol—chronic obstructive pulmonary disease	2.12e-05	0.000562	CcSEcCtD
Arformoterol—Infection—Formoterol—chronic obstructive pulmonary disease	2.11e-05	0.000559	CcSEcCtD
Arformoterol—Myalgia—Salbutamol—chronic obstructive pulmonary disease	2.09e-05	0.000555	CcSEcCtD
Arformoterol—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	2.09e-05	0.000555	CcSEcCtD
Arformoterol—Chest pain—Salbutamol—chronic obstructive pulmonary disease	2.09e-05	0.000555	CcSEcCtD
Arformoterol—Urticaria—Tiotropium—chronic obstructive pulmonary disease	2.09e-05	0.000554	CcSEcCtD
Arformoterol—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	2.08e-05	0.00432	CbGpPWpGaD
Arformoterol—Anxiety—Salbutamol—chronic obstructive pulmonary disease	2.08e-05	0.000553	CcSEcCtD
Arformoterol—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	2.08e-05	0.000552	CcSEcCtD
Arformoterol—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	2.08e-05	0.000552	CcSEcCtD
Arformoterol—Oedema—Montelukast—chronic obstructive pulmonary disease	2.08e-05	0.000552	CcSEcCtD
Arformoterol—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	2.08e-05	0.000552	CcSEcCtD
Arformoterol—Tachycardia—Formoterol—chronic obstructive pulmonary disease	2.07e-05	0.00055	CcSEcCtD
Arformoterol—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	2.06e-05	0.00428	CbGpPWpGaD
Arformoterol—Discomfort—Salbutamol—chronic obstructive pulmonary disease	2.06e-05	0.000548	CcSEcCtD
Arformoterol—Infection—Montelukast—chronic obstructive pulmonary disease	2.06e-05	0.000548	CcSEcCtD
Arformoterol—Skin disorder—Formoterol—chronic obstructive pulmonary disease	2.06e-05	0.000547	CcSEcCtD
Arformoterol—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	2.05e-05	0.000545	CcSEcCtD
Arformoterol—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	2.04e-05	0.000542	CcSEcCtD
Arformoterol—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	2.04e-05	0.000541	CcSEcCtD
Arformoterol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	2.03e-05	0.00422	CbGpPWpGaD
Arformoterol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	2.02e-05	0.00419	CbGpPWpGaD
Arformoterol—ADRB1—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	2.02e-05	0.00418	CbGpPWpGaD
Arformoterol—Skin disorder—Montelukast—chronic obstructive pulmonary disease	2.02e-05	0.000536	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—TGFB2—chronic obstructive pulmonary disease	2.01e-05	0.00417	CbGpPWpGaD
Arformoterol—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	2.01e-05	0.00417	CbGpPWpGaD
Arformoterol—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	2e-05	0.000532	CcSEcCtD
Arformoterol—Oedema—Salbutamol—chronic obstructive pulmonary disease	2e-05	0.000532	CcSEcCtD
Arformoterol—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	1.99e-05	0.00413	CbGpPWpGaD
Arformoterol—Infection—Salbutamol—chronic obstructive pulmonary disease	1.99e-05	0.000528	CcSEcCtD
Arformoterol—Hypotension—Formoterol—chronic obstructive pulmonary disease	1.98e-05	0.000526	CcSEcCtD
Arformoterol—ADRB2—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	1.97e-05	0.0041	CbGpPWpGaD
Arformoterol—Pruritus—Aminophylline—chronic obstructive pulmonary disease	1.97e-05	0.000523	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—SLC6A4—chronic obstructive pulmonary disease	1.97e-05	0.00409	CbGpPWpGaD
Arformoterol—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	1.96e-05	0.000521	CcSEcCtD
Arformoterol—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	1.95e-05	0.000519	CcSEcCtD
Arformoterol—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	1.94e-05	0.000516	CcSEcCtD
Arformoterol—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	1.93e-05	0.000514	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	1.93e-05	0.000513	CcSEcCtD
Arformoterol—Insomnia—Formoterol—chronic obstructive pulmonary disease	1.92e-05	0.000509	CcSEcCtD
Arformoterol—ADRB2—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	1.92e-05	0.00398	CbGpPWpGaD
Arformoterol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	1.9e-05	0.000506	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	1.89e-05	0.000503	CcSEcCtD
Arformoterol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	1.89e-05	0.000502	CcSEcCtD
Arformoterol—Somnolence—Formoterol—chronic obstructive pulmonary disease	1.88e-05	0.000501	CcSEcCtD
Arformoterol—CYP2A6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.88e-05	0.0039	CbGpPWpGaD
Arformoterol—Insomnia—Montelukast—chronic obstructive pulmonary disease	1.88e-05	0.000499	CcSEcCtD
Arformoterol—Cardiac failure congestive—Prednisone—chronic obstructive pulmonary disease	1.87e-05	0.000497	CcSEcCtD
Arformoterol—Hypotension—Salbutamol—chronic obstructive pulmonary disease	1.87e-05	0.000497	CcSEcCtD
Arformoterol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	1.87e-05	0.000496	CcSEcCtD
Arformoterol—CYP2C19—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	1.86e-05	0.00386	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.86e-05	0.00386	CbGpPWpGaD
Arformoterol—Pruritus—Tiotropium—chronic obstructive pulmonary disease	1.86e-05	0.000494	CcSEcCtD
Arformoterol—Injury—Prednisone—chronic obstructive pulmonary disease	1.85e-05	0.000491	CcSEcCtD
Arformoterol—Somnolence—Montelukast—chronic obstructive pulmonary disease	1.85e-05	0.00049	CcSEcCtD
Arformoterol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	1.84e-05	0.000489	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	1.83e-05	0.000486	CcSEcCtD
Arformoterol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	1.83e-05	0.000486	CcSEcCtD
Arformoterol—Fatigue—Formoterol—chronic obstructive pulmonary disease	1.83e-05	0.000485	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	1.82e-05	0.000484	CcSEcCtD
Arformoterol—Pain—Formoterol—chronic obstructive pulmonary disease	1.81e-05	0.000482	CcSEcCtD
Arformoterol—Constipation—Formoterol—chronic obstructive pulmonary disease	1.81e-05	0.000482	CcSEcCtD
Arformoterol—Insomnia—Salbutamol—chronic obstructive pulmonary disease	1.81e-05	0.000481	CcSEcCtD
Arformoterol—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	1.79e-05	0.00372	CbGpPWpGaD
Arformoterol—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	1.79e-05	0.000476	CcSEcCtD
Arformoterol—Fatigue—Montelukast—chronic obstructive pulmonary disease	1.79e-05	0.000476	CcSEcCtD
Arformoterol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	1.79e-05	0.00371	CbGpPWpGaD
Arformoterol—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	1.78e-05	0.000474	CcSEcCtD
Arformoterol—Somnolence—Salbutamol—chronic obstructive pulmonary disease	1.78e-05	0.000473	CcSEcCtD
Arformoterol—Pain—Montelukast—chronic obstructive pulmonary disease	1.77e-05	0.000472	CcSEcCtD
Arformoterol—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	1.77e-05	0.000471	CcSEcCtD
Arformoterol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	1.77e-05	0.00047	CcSEcCtD
Arformoterol—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	1.76e-05	0.000469	CcSEcCtD
Arformoterol—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	1.76e-05	0.000468	CcSEcCtD
Arformoterol—Rash—Aminophylline—chronic obstructive pulmonary disease	1.76e-05	0.000467	CcSEcCtD
Arformoterol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	1.75e-05	0.000466	CcSEcCtD
Arformoterol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	1.75e-05	0.00363	CbGpPWpGaD
Arformoterol—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	1.75e-05	0.000465	CcSEcCtD
Arformoterol—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	1.75e-05	0.000464	CcSEcCtD
Arformoterol—Headache—Aminophylline—chronic obstructive pulmonary disease	1.74e-05	0.000464	CcSEcCtD
Arformoterol—ADRB1—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	1.74e-05	0.00361	CbGpPWpGaD
Arformoterol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	1.74e-05	0.000461	CcSEcCtD
Arformoterol—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	1.73e-05	0.00046	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	1.73e-05	0.000459	CcSEcCtD
Arformoterol—Fatigue—Salbutamol—chronic obstructive pulmonary disease	1.72e-05	0.000458	CcSEcCtD
Arformoterol—Pain—Salbutamol—chronic obstructive pulmonary disease	1.71e-05	0.000455	CcSEcCtD
Arformoterol—Constipation—Salbutamol—chronic obstructive pulmonary disease	1.71e-05	0.000455	CcSEcCtD
Arformoterol—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	1.7e-05	0.000451	CcSEcCtD
Arformoterol—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	1.7e-05	0.00352	CbGpPWpGaD
Arformoterol—Urticaria—Formoterol—chronic obstructive pulmonary disease	1.68e-05	0.000447	CcSEcCtD
Arformoterol—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	1.68e-05	0.000445	CcSEcCtD
Arformoterol—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	1.68e-05	0.000445	CcSEcCtD
Arformoterol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	1.67e-05	0.000444	CcSEcCtD
Arformoterol—Rash—Tiotropium—chronic obstructive pulmonary disease	1.66e-05	0.00044	CcSEcCtD
Arformoterol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	1.65e-05	0.00044	CcSEcCtD
Arformoterol—Nausea—Aminophylline—chronic obstructive pulmonary disease	1.65e-05	0.000439	CcSEcCtD
Arformoterol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	1.65e-05	0.00342	CbGpPWpGaD
Arformoterol—Urticaria—Montelukast—chronic obstructive pulmonary disease	1.65e-05	0.000438	CcSEcCtD
Arformoterol—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	1.65e-05	0.000438	CcSEcCtD
Arformoterol—Headache—Tiotropium—chronic obstructive pulmonary disease	1.64e-05	0.000437	CcSEcCtD
Arformoterol—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	1.64e-05	0.000436	CcSEcCtD
Arformoterol—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	1.64e-05	0.000436	CcSEcCtD
Arformoterol—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	1.64e-05	0.000435	CcSEcCtD
Arformoterol—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	1.63e-05	0.00339	CbGpPWpGaD
Arformoterol—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	1.61e-05	0.00334	CbGpPWpGaD
Arformoterol—Urticaria—Salbutamol—chronic obstructive pulmonary disease	1.59e-05	0.000422	CcSEcCtD
Arformoterol—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	1.59e-05	0.00329	CbGpPWpGaD
Arformoterol—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	1.58e-05	0.00042	CcSEcCtD
Arformoterol—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	1.58e-05	0.00042	CcSEcCtD
Arformoterol—CYP2A6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	1.56e-05	0.00324	CbGpPWpGaD
Arformoterol—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	1.56e-05	0.000415	CcSEcCtD
Arformoterol—Nausea—Tiotropium—chronic obstructive pulmonary disease	1.56e-05	0.000414	CcSEcCtD
Arformoterol—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	1.56e-05	0.000414	CcSEcCtD
Arformoterol—Dry skin—Prednisone—chronic obstructive pulmonary disease	1.56e-05	0.000413	CcSEcCtD
Arformoterol—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	1.54e-05	0.00041	CcSEcCtD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.53e-05	0.00318	CbGpPWpGaD
Arformoterol—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	1.53e-05	0.000406	CcSEcCtD
Arformoterol—Asthenia—Formoterol—chronic obstructive pulmonary disease	1.52e-05	0.000404	CcSEcCtD
Arformoterol—CYP2A6—Fluoropyrimidine Activity—TP53—chronic obstructive pulmonary disease	1.51e-05	0.00312	CbGpPWpGaD
Arformoterol—Pruritus—Formoterol—chronic obstructive pulmonary disease	1.5e-05	0.000398	CcSEcCtD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	1.5e-05	0.00311	CbGpPWpGaD
Arformoterol—Asthenia—Montelukast—chronic obstructive pulmonary disease	1.49e-05	0.000396	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—GSTP1—chronic obstructive pulmonary disease	1.49e-05	0.00308	CbGpPWpGaD
Arformoterol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	1.48e-05	0.00307	CbGpPWpGaD
Arformoterol—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	1.47e-05	0.000392	CcSEcCtD
Arformoterol—Pruritus—Montelukast—chronic obstructive pulmonary disease	1.47e-05	0.00039	CcSEcCtD
Arformoterol—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	1.47e-05	0.00304	CbGpPWpGaD
Arformoterol—CYP2A6—NRF2 pathway—HMOX1—chronic obstructive pulmonary disease	1.47e-05	0.00304	CbGpPWpGaD
Arformoterol—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	1.46e-05	0.00303	CbGpPWpGaD
Arformoterol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	1.45e-05	0.000385	CcSEcCtD
Arformoterol—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	1.45e-05	0.003	CbGpPWpGaD
Arformoterol—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	1.44e-05	0.000383	CcSEcCtD
Arformoterol—Asthenia—Salbutamol—chronic obstructive pulmonary disease	1.44e-05	0.000381	CcSEcCtD
Arformoterol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	1.42e-05	0.000377	CcSEcCtD
Arformoterol—Pruritus—Salbutamol—chronic obstructive pulmonary disease	1.42e-05	0.000376	CcSEcCtD
Arformoterol—Dizziness—Formoterol—chronic obstructive pulmonary disease	1.4e-05	0.000372	CcSEcCtD
Arformoterol—Dizziness—Montelukast—chronic obstructive pulmonary disease	1.37e-05	0.000365	CcSEcCtD
Arformoterol—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	1.37e-05	0.000364	CcSEcCtD
Arformoterol—CYP2A6—NRF2 pathway—GSTM1—chronic obstructive pulmonary disease	1.37e-05	0.00283	CbGpPWpGaD
Arformoterol—Vomiting—Formoterol—chronic obstructive pulmonary disease	1.35e-05	0.000358	CcSEcCtD
Arformoterol—Rash—Formoterol—chronic obstructive pulmonary disease	1.34e-05	0.000355	CcSEcCtD
Arformoterol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	1.33e-05	0.000355	CcSEcCtD
Arformoterol—Headache—Formoterol—chronic obstructive pulmonary disease	1.33e-05	0.000353	CcSEcCtD
Arformoterol—Dizziness—Salbutamol—chronic obstructive pulmonary disease	1.32e-05	0.000352	CcSEcCtD
Arformoterol—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	1.32e-05	0.000352	CcSEcCtD
Arformoterol—Vomiting—Montelukast—chronic obstructive pulmonary disease	1.32e-05	0.000351	CcSEcCtD
Arformoterol—Rash—Montelukast—chronic obstructive pulmonary disease	1.31e-05	0.000348	CcSEcCtD
Arformoterol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	1.31e-05	0.000347	CcSEcCtD
Arformoterol—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	1.3e-05	0.000347	CcSEcCtD
Arformoterol—CYP2A6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.3e-05	0.0027	CbGpPWpGaD
Arformoterol—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.3e-05	0.0027	CbGpPWpGaD
Arformoterol—Headache—Montelukast—chronic obstructive pulmonary disease	1.3e-05	0.000346	CcSEcCtD
Arformoterol—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	1.29e-05	0.000343	CcSEcCtD
Arformoterol—Angioedema—Prednisolone—chronic obstructive pulmonary disease	1.28e-05	0.000341	CcSEcCtD
Arformoterol—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	1.28e-05	0.000341	CcSEcCtD
Arformoterol—Vomiting—Salbutamol—chronic obstructive pulmonary disease	1.27e-05	0.000338	CcSEcCtD
Arformoterol—Malaise—Prednisolone—chronic obstructive pulmonary disease	1.27e-05	0.000337	CcSEcCtD
Arformoterol—Rash—Salbutamol—chronic obstructive pulmonary disease	1.26e-05	0.000335	CcSEcCtD
Arformoterol—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	1.26e-05	0.000335	CcSEcCtD
Arformoterol—Nausea—Formoterol—chronic obstructive pulmonary disease	1.26e-05	0.000334	CcSEcCtD
Arformoterol—Headache—Salbutamol—chronic obstructive pulmonary disease	1.25e-05	0.000333	CcSEcCtD
Arformoterol—Nausea—Montelukast—chronic obstructive pulmonary disease	1.23e-05	0.000328	CcSEcCtD
Arformoterol—Hypertension—Prednisolone—chronic obstructive pulmonary disease	1.21e-05	0.000323	CcSEcCtD
Arformoterol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.2e-05	0.00249	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.2e-05	0.00249	CbGpPWpGaD
Arformoterol—Nausea—Salbutamol—chronic obstructive pulmonary disease	1.19e-05	0.000316	CcSEcCtD
Arformoterol—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	1.19e-05	0.00247	CbGpPWpGaD
Arformoterol—Discomfort—Prednisolone—chronic obstructive pulmonary disease	1.18e-05	0.000314	CcSEcCtD
Arformoterol—ADRB1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.17e-05	0.00242	CbGpPWpGaD
Arformoterol—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	1.15e-05	0.000307	CcSEcCtD
Arformoterol—Oedema—Prednisolone—chronic obstructive pulmonary disease	1.15e-05	0.000305	CcSEcCtD
Arformoterol—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	1.15e-05	0.000305	CcSEcCtD
Arformoterol—CYP2C19—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.15e-05	0.00238	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	1.14e-05	0.00237	CbGpPWpGaD
Arformoterol—CYP2A6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.14e-05	0.00236	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.13e-05	0.00235	CbGpPWpGaD
Arformoterol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	1.12e-05	0.00233	CbGpPWpGaD
Arformoterol—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	1.12e-05	0.000298	CcSEcCtD
Arformoterol—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	1.06e-05	0.000282	CcSEcCtD
Arformoterol—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.05e-05	0.00219	CbGpPWpGaD
Arformoterol—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	1.05e-05	0.000279	CcSEcCtD
Arformoterol—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	1.05e-05	0.00217	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.04e-05	0.00216	CbGpPWpGaD
Arformoterol—Insomnia—Prednisolone—chronic obstructive pulmonary disease	1.04e-05	0.000276	CcSEcCtD
Arformoterol—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	1.03e-05	0.00214	CbGpPWpGaD
Arformoterol—Mental disorder—Prednisone—chronic obstructive pulmonary disease	1.03e-05	0.000273	CcSEcCtD
Arformoterol—Malnutrition—Prednisone—chronic obstructive pulmonary disease	1.02e-05	0.000272	CcSEcCtD
Arformoterol—Pain—Prednisolone—chronic obstructive pulmonary disease	9.81e-06	0.000261	CcSEcCtD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	9.61e-06	0.002	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	9.56e-06	0.00198	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.52e-06	0.00198	CbGpPWpGaD
Arformoterol—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	9.48e-06	0.000252	CcSEcCtD
Arformoterol—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	9.46e-06	0.000251	CcSEcCtD
Arformoterol—CYP2C19—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.39e-06	0.00195	CbGpPWpGaD
Arformoterol—Agitation—Prednisone—chronic obstructive pulmonary disease	9.39e-06	0.00025	CcSEcCtD
Arformoterol—ADRB2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	9.35e-06	0.00194	CbGpPWpGaD
Arformoterol—Angioedema—Prednisone—chronic obstructive pulmonary disease	9.34e-06	0.000248	CcSEcCtD
Arformoterol—Malaise—Prednisone—chronic obstructive pulmonary disease	9.21e-06	0.000245	CcSEcCtD
Arformoterol—CYP2A6—Metabolism—APIP—chronic obstructive pulmonary disease	9.13e-06	0.0019	CbGpPWpGaD
Arformoterol—Urticaria—Prednisolone—chronic obstructive pulmonary disease	9.12e-06	0.000242	CcSEcCtD
Arformoterol—Hypertension—Prednisone—chronic obstructive pulmonary disease	8.82e-06	0.000234	CcSEcCtD
Arformoterol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	8.77e-06	0.00182	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.76e-06	0.00182	CbGpPWpGaD
Arformoterol—Arthralgia—Prednisone—chronic obstructive pulmonary disease	8.7e-06	0.000231	CcSEcCtD
Arformoterol—Myalgia—Prednisone—chronic obstructive pulmonary disease	8.7e-06	0.000231	CcSEcCtD
Arformoterol—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	8.68e-06	0.0018	CbGpPWpGaD
Arformoterol—Anxiety—Prednisone—chronic obstructive pulmonary disease	8.67e-06	0.00023	CcSEcCtD
Arformoterol—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.64e-06	0.00179	CbGpPWpGaD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	8.64e-06	0.00023	CcSEcCtD
Arformoterol—Discomfort—Prednisone—chronic obstructive pulmonary disease	8.59e-06	0.000228	CcSEcCtD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	8.59e-06	0.00178	CbGpPWpGaD
Arformoterol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	8.58e-06	0.00178	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.57e-06	0.00178	CbGpPWpGaD
Arformoterol—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	8.45e-06	0.000225	CcSEcCtD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	8.4e-06	0.00174	CbGpPWpGaD
Arformoterol—Oedema—Prednisone—chronic obstructive pulmonary disease	8.34e-06	0.000222	CcSEcCtD
Arformoterol—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	8.34e-06	0.000222	CcSEcCtD
Arformoterol—Infection—Prednisone—chronic obstructive pulmonary disease	8.28e-06	0.00022	CcSEcCtD
Arformoterol—ADRB1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	8.18e-06	0.0017	CbGpPWpGaD
Arformoterol—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	8.18e-06	0.000217	CcSEcCtD
Arformoterol—Tachycardia—Prednisone—chronic obstructive pulmonary disease	8.14e-06	0.000216	CcSEcCtD
Arformoterol—Skin disorder—Prednisone—chronic obstructive pulmonary disease	8.1e-06	0.000215	CcSEcCtD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	8.06e-06	0.00167	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	8e-06	0.00166	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.94e-06	0.00165	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.84e-06	0.00163	CbGpPWpGaD
Arformoterol—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	7.6e-06	0.000202	CcSEcCtD
Arformoterol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	7.59e-06	0.000202	CcSEcCtD
Arformoterol—Insomnia—Prednisone—chronic obstructive pulmonary disease	7.54e-06	0.0002	CcSEcCtD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	7.51e-06	0.00156	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	7.43e-06	0.00154	CbGpPWpGaD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	7.35e-06	0.00153	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	7.35e-06	0.00152	CbGpPWpGaD
Arformoterol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	7.34e-06	0.000195	CcSEcCtD
Arformoterol—ADRB1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	7.32e-06	0.00152	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.31e-06	0.00152	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.3e-06	0.00152	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	7.27e-06	0.00151	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.24e-06	0.0015	CbGpPWpGaD
Arformoterol—Rash—Prednisolone—chronic obstructive pulmonary disease	7.24e-06	0.000192	CcSEcCtD
Arformoterol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	7.23e-06	0.000192	CcSEcCtD
Arformoterol—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.21e-06	0.0015	CbGpPWpGaD
Arformoterol—CYP2C19—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.2e-06	0.00149	CbGpPWpGaD
Arformoterol—Fatigue—Prednisone—chronic obstructive pulmonary disease	7.19e-06	0.000191	CcSEcCtD
Arformoterol—Headache—Prednisolone—chronic obstructive pulmonary disease	7.19e-06	0.000191	CcSEcCtD
Arformoterol—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.14e-06	0.00148	CbGpPWpGaD
Arformoterol—Constipation—Prednisone—chronic obstructive pulmonary disease	7.13e-06	0.00019	CcSEcCtD
Arformoterol—CYP2C19—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.92e-06	0.00144	CbGpPWpGaD
Arformoterol—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	6.87e-06	0.000183	CcSEcCtD
Arformoterol—CYP2C19—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.83e-06	0.00142	CbGpPWpGaD
Arformoterol—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	6.82e-06	0.000181	CcSEcCtD
Arformoterol—Nausea—Prednisolone—chronic obstructive pulmonary disease	6.82e-06	0.000181	CcSEcCtD
Arformoterol—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.71e-06	0.00139	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.66e-06	0.00138	CbGpPWpGaD
Arformoterol—Urticaria—Prednisone—chronic obstructive pulmonary disease	6.62e-06	0.000176	CcSEcCtD
Arformoterol—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.62e-06	0.00137	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	6.59e-06	0.00137	CbGpPWpGaD
Arformoterol—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	6.59e-06	0.000175	CcSEcCtD
Arformoterol—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	6.59e-06	0.000175	CcSEcCtD
Arformoterol—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.57e-06	0.00136	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	6.54e-06	0.00136	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	6.45e-06	0.00134	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	6.4e-06	0.00133	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.37e-06	0.00132	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.31e-06	0.00131	CbGpPWpGaD
Arformoterol—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.28e-06	0.0013	CbGpPWpGaD
Arformoterol—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.22e-06	0.00129	CbGpPWpGaD
Arformoterol—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	6.14e-06	0.000163	CcSEcCtD
Arformoterol—CYP2A6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.05e-06	0.00126	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.99e-06	0.00124	CbGpPWpGaD
Arformoterol—Asthenia—Prednisone—chronic obstructive pulmonary disease	5.98e-06	0.000159	CcSEcCtD
Arformoterol—Pruritus—Prednisone—chronic obstructive pulmonary disease	5.9e-06	0.000157	CcSEcCtD
Arformoterol—CYP2A6—Metabolism—GC—chronic obstructive pulmonary disease	5.88e-06	0.00122	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.86e-06	0.00122	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.79e-06	0.0012	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.72e-06	0.00119	CbGpPWpGaD
Arformoterol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	5.71e-06	0.000152	CcSEcCtD
Arformoterol—ADRB2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.66e-06	0.00118	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.6e-06	0.00116	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—APIP—chronic obstructive pulmonary disease	5.57e-06	0.00116	CbGpPWpGaD
Arformoterol—CYP2A6—NRF2 pathway—TGFB1—chronic obstructive pulmonary disease	5.56e-06	0.00115	CbGpPWpGaD
Arformoterol—Dizziness—Prednisone—chronic obstructive pulmonary disease	5.51e-06	0.000147	CcSEcCtD
Arformoterol—CYP2A6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.47e-06	0.00114	CbGpPWpGaD
Arformoterol—Vomiting—Prednisone—chronic obstructive pulmonary disease	5.3e-06	0.000141	CcSEcCtD
Arformoterol—Rash—Prednisone—chronic obstructive pulmonary disease	5.26e-06	0.00014	CcSEcCtD
Arformoterol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	5.25e-06	0.00014	CcSEcCtD
Arformoterol—Headache—Prednisone—chronic obstructive pulmonary disease	5.22e-06	0.000139	CcSEcCtD
Arformoterol—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	5.12e-06	0.00106	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	5.08e-06	0.00105	CbGpPWpGaD
Arformoterol—Nausea—Prednisone—chronic obstructive pulmonary disease	4.95e-06	0.000132	CcSEcCtD
Arformoterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.64e-06	0.000964	CbGpPWpGaD
Arformoterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.54e-06	0.000943	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.39e-06	0.000911	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.29e-06	0.000891	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.14e-06	0.000859	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.97e-06	0.000824	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.76e-06	0.00078	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.7e-06	0.000767	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.69e-06	0.000766	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.66e-06	0.000759	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.62e-06	0.000751	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.62e-06	0.00075	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GC—chronic obstructive pulmonary disease	3.59e-06	0.000745	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.54e-06	0.000734	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.53e-06	0.000734	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.46e-06	0.000718	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.46e-06	0.000718	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.39e-06	0.000704	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.36e-06	0.000698	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.36e-06	0.000697	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.34e-06	0.000692	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.33e-06	0.000692	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	3.3e-06	0.000685	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.28e-06	0.000682	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	3.27e-06	0.000679	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.23e-06	0.000671	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.21e-06	0.000667	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GCLC—chronic obstructive pulmonary disease	3.18e-06	0.00066	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.16e-06	0.000657	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.07e-06	0.000637	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.04e-06	0.000631	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.94e-06	0.000609	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CTGF—chronic obstructive pulmonary disease	2.9e-06	0.000602	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.87e-06	0.000596	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.67e-06	0.000555	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.66e-06	0.000552	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.59e-06	0.000537	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.53e-06	0.000525	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.42e-06	0.000503	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.4e-06	0.000499	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.35e-06	0.000488	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.23e-06	0.000463	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.22e-06	0.000461	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.2e-06	0.000456	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.05e-06	0.000425	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	2e-06	0.000415	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.98e-06	0.000412	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.96e-06	0.000407	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.95e-06	0.000406	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.94e-06	0.000403	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.94e-06	0.000403	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GCLC—chronic obstructive pulmonary disease	1.94e-06	0.000402	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.81e-06	0.000377	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.81e-06	0.000375	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.8e-06	0.000374	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.8e-06	0.000374	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.79e-06	0.000371	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.78e-06	0.00037	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.77e-06	0.000368	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CTGF—chronic obstructive pulmonary disease	1.77e-06	0.000367	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.77e-06	0.000367	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.76e-06	0.000366	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.73e-06	0.00036	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.7e-06	0.000352	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.65e-06	0.000342	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.63e-06	0.000338	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.63e-06	0.000338	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.61e-06	0.000335	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.61e-06	0.000335	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.58e-06	0.000327	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.5e-06	0.000311	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.49e-06	0.000308	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.36e-06	0.000282	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.34e-06	0.000278	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.33e-06	0.000275	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ALB—chronic obstructive pulmonary disease	1.32e-06	0.000274	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.3e-06	0.000269	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.27e-06	0.000263	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—NOS3—chronic obstructive pulmonary disease	1.26e-06	0.000262	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.25e-06	0.000259	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.25e-06	0.000259	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.24e-06	0.000257	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.24e-06	0.000257	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.23e-06	0.000256	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.22e-06	0.000254	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.21e-06	0.000251	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.18e-06	0.000246	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.18e-06	0.000245	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.15e-06	0.000238	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.14e-06	0.000236	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.09e-06	0.000226	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.08e-06	0.000224	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.07e-06	0.000222	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.05e-06	0.000218	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	1.02e-06	0.000212	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.97e-07	0.000207	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.69e-07	0.000201	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.48e-07	0.000197	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.7e-07	0.000181	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.51e-07	0.000177	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALB—chronic obstructive pulmonary disease	8.04e-07	0.000167	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.99e-07	0.000166	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.83e-07	0.000163	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.81e-07	0.000162	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—NOS3—chronic obstructive pulmonary disease	7.7e-07	0.00016	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.66e-07	0.000159	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	7.4e-07	0.000154	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	7.34e-07	0.000152	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	7.08e-07	0.000147	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	7.02e-07	0.000146	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.58e-07	0.000137	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.43e-07	0.000134	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	6.02e-07	0.000125	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.89e-07	0.000122	CbGpPWpGaD
